Ann: Imugene Advances to Phase 2 in Gastric Cancer Trial, page-150

FP,

max 4 weeks to the in detailed phase 1b update, the positioning seems to have started as in the past days not many people were willing to sell despite the market jitters.

One thing that separates IMU from other Bio-techs is the CV and the motives of our management compared to the others - 100% to find a cure.

Prof. Wiedermann is a vaxx - guru and working at the Vienna uni means to research without the chance of getting filthy rich in case of success. Our CEO is motivated due to her loss of family members and the obstacles put in her way or not willingness of her former employer to go the immune system - therapy way. AH and PH may have a greater financial gain interest but even they put a cure before the money. Therefore any infos we got so far can be taken as absolutely trustworthy - they haven't put it out to drive the sp up for personal financial gain. And that is sensed by the bigger guys for a while who obviously think is time to end the waiting game.

When LC was talking about the sp she always had IMU's account in her mind, not her personal one.

They gave us enough hints between the lines, it was plenty of time to pick up heads for 2c - just patience was required.

GLTA, especially to those who need the cure by " yesterday ".